Nuveen’s MoonLake Immunotherapeutics MLTX Stock Holding History

Nuveen’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$951K	Buy	48,835 +15,418	+46%	+$279K	﹤0.01%	2964
2026 Q1	$623K	Sell	33,417 -604,017	-95%	-$10M	﹤0.01%	2760
2025 Q4	$8.4M	Buy	637,434 +1,735	+0.3%	+$20.5K	﹤0.01%	1657
2025 Q3	$4.56M	Sell	635,699 -155,856	-20%	-$8.12M	﹤0.01%	1950
2025 Q2	$37.4M	Buy	791,555 +118,212	+18%	+$4.82M	0.01%	738
2025 Q1	$26.3M	Buy	673,343 +77,762	+13%	+$3.35M	0.01%	950
2024 Q4	$32.3M	Buy	595,581 +14,792	+3%	+$755K	0.01%	872
2024 Q3	$29.3M	Buy	580,789 +59,076	+11%	+$2.77M	0.01%	943
2024 Q2	$22.9M	Buy	521,713 +325,842	+166%	+$13.8M	0.01%	1040
2024 Q1	$9.84M	Sell	195,871 -444	-0.2%	-$24.1K	﹤0.01%	1593
2023 Q4	$11.9M	Buy	196,315 +56,315	+40%	+$2.9M	﹤0.01%	1485
2023 Q3	$7.98M	Hold	140,000	–	–	﹤0.01%	1608
2023 Q2	$7.14M	Buy	+140,000	New	+$3.77M	﹤0.01%	1712

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's MLTX Position: Q2 2026 in Review

Nuveen increased its MoonLake Immunotherapeutics (MLTX) stake by 46% in Q2 2026, buying an estimated $279K and bringing the position to 48,835 shares worth $951K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

Nuveen first reported a position in MLTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $37.4M in Q2 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Nuveen held 48,835 shares of MoonLake Immunotherapeutics worth $951K as of Q2 2026.
Nuveen bought 15,418 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $279K.
MoonLake Immunotherapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2964 holding.
Nuveen first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 13 quarters since.
Nuveen's MoonLake Immunotherapeutics position peaked at $37.4M in Q2 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.